Topic: Personal Point of View about Targeted Therapy at this Moment
As of this moment, targeted therapy is expensive and may not provide reasonable cost effectiveness and benefit to CCA patients either in mono or combined with chemo agents.(ie:ipilimumab,depends on venders,the wholesale cost each is about 50,000 US doollars;not counting profit margin and overhead cost for the institution.)
For those who CAN choose the clinical trials to join ;it is always better to join those which are in the middle or at the end of phase II trials or the best if you can join in phase III ,which is highly unlikely. I will avoid,if I can, the phase one trials for new agents and will choose the current available chemotherapy regimens first; if it doesn't work ;then try another chemotherapy combined with a targeted agent which has been evaluated for a period of time(ie: Avastin as compare of the newer EGFR inhibitors. As a patient myself, I am not against phase I trails ,but if you have options of between phase I and phase II;choose phase II is more safe because by then the researchers would know pretty much about the adverse events and appropriate dosage and schedule of the tested regimen or agent .